交易 Karuna Therapeutics, Inc. - KRTX CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
价差 | 0.51 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Karuna Therapeutics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Jun 8, 2023 | 233.49 | 3.63 | 1.58% | 229.86 | 235.43 | 228.88 |
Jun 7, 2023 | 231.83 | -2.17 | -0.93% | 234.00 | 237.51 | 231.74 |
Jun 6, 2023 | 236.16 | 6.45 | 2.81% | 229.71 | 238.28 | 228.86 |
Jun 5, 2023 | 234.13 | 6.81 | 3.00% | 227.32 | 235.55 | 227.31 |
Jun 2, 2023 | 233.29 | 8.55 | 3.80% | 224.74 | 233.88 | 224.74 |
Jun 1, 2023 | 228.91 | 2.49 | 1.10% | 226.42 | 229.64 | 224.61 |
May 31, 2023 | 226.07 | 12.64 | 5.92% | 213.43 | 226.64 | 213.43 |
May 30, 2023 | 220.87 | 3.00 | 1.38% | 217.87 | 221.57 | 216.90 |
May 26, 2023 | 219.88 | 6.00 | 2.81% | 213.88 | 220.62 | 213.87 |
May 25, 2023 | 219.68 | -0.40 | -0.18% | 220.08 | 222.38 | 218.77 |
May 24, 2023 | 224.14 | 2.46 | 1.11% | 221.68 | 224.63 | 217.06 |
May 23, 2023 | 222.34 | -1.52 | -0.68% | 223.86 | 226.15 | 220.58 |
May 22, 2023 | 225.37 | 0.47 | 0.21% | 224.90 | 227.69 | 223.86 |
May 19, 2023 | 223.68 | 9.29 | 4.33% | 214.39 | 224.09 | 214.39 |
May 18, 2023 | 218.29 | -0.38 | -0.17% | 218.67 | 221.22 | 213.28 |
May 17, 2023 | 220.08 | -1.29 | -0.58% | 221.37 | 223.20 | 217.23 |
May 16, 2023 | 222.52 | 3.19 | 1.45% | 219.33 | 224.77 | 214.79 |
May 15, 2023 | 230.48 | 11.14 | 5.08% | 219.34 | 232.00 | 219.33 |
May 12, 2023 | 227.84 | 2.41 | 1.07% | 225.43 | 230.01 | 224.86 |
May 11, 2023 | 227.58 | 10.11 | 4.65% | 217.47 | 228.30 | 217.46 |
Karuna Therapeutics, Inc. Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Monday, June 12, 2023 | ||
时间(协调世界时) (UTC) 21:40 | 国家/地区 US
| 事件 Karuna Therapeutics Inc at Goldman Sachs Healthcare Conference Karuna Therapeutics Inc at Goldman Sachs Healthcare ConferenceForecast -Previous - |
Thursday, June 15, 2023 | ||
时间(协调世界时) (UTC) 14:00 | 国家/地区 US
| 事件 Karuna Therapeutics Inc Annual Shareholders Meeting Karuna Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Tuesday, June 20, 2023 | ||
时间(协调世界时) (UTC) 13:00 | 国家/地区 US
| 事件 Karuna Therapeutics Inc Annual Shareholders Meeting Karuna Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
时间(协调世界时) (UTC) 12:30 | 国家/地区 US
| 事件 Q2 2023 Karuna Therapeutics Inc Earnings Release Q2 2023 Karuna Therapeutics Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 1, 2023 | ||
时间(协调世界时) (UTC) 12:30 | 国家/地区 US
| 事件 Q3 2023 Karuna Therapeutics Inc Earnings Release Q3 2023 Karuna Therapeutics Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 10.637 | 36.964 | 0 | 0 | 0 |
收入 | 10.637 | 36.964 | 0 | 0 | 0 |
总营业费用 | 300.313 | 181.519 | 71.816 | 45.405 | 14.51 |
销售/一般/行政费用,总计 | 76.066 | 52.617 | 28.408 | 20.869 | 2.974 |
研究与开发 | 224.247 | 128.2 | 43.408 | 24.536 | 11.536 |
营业收入 | -289.676 | -144.555 | -71.816 | -45.405 | -14.51 |
利息收入(费用),非经营净值 | 14.178 | 0.502 | 3.305 | 1.448 | -3.002 |
税前净收入 | -274.918 | -143.799 | -68.511 | -43.957 | -17.512 |
税后净收入 | -276.336 | -143.805 | -68.554 | -43.957 | -17.512 |
未计算非常项目前的净收益 | -276.336 | -143.805 | -68.554 | -43.957 | -17.512 |
净收入 | -276.336 | -143.805 | -68.554 | -43.957 | -17.512 |
普通股股东可获收益 (不含非经常性项目) | -276.336 | -143.805 | -68.554 | -43.957 | -17.512 |
普通股股东可获收益 (含非經常性項目) | -276.336 | -143.805 | -68.554 | -43.957 | -17.512 |
摊薄净收入 | -276.336 | -143.805 | -68.554 | -43.957 | -17.512 |
摊薄后加权平均股 | 31.629 | 29.1389 | 26.446 | 26.0128 | 21.3729 |
扣除特别项目的每股摊薄盈利 | -8.73679 | -4.93515 | -2.59223 | -1.68982 | -0.81935 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
每股正常摊薄盈利 | -8.73679 | -4.91949 | -2.59223 | -1.68982 | -0.81935 |
异常费用(收入) | 0 | 0.702 | |||
其他,净值 | 0.58 | 0.254 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 0.654 | 5.278 | 0.081 | 5.278 | 0 |
收入 | 0.654 | 5.278 | 0.081 | 5.278 | 0 |
总营业费用 | 109.72 | 90.314 | 81.075 | 70.33 | 58.594 |
销售/一般/行政费用,总计 | 24.253 | 24.31 | 19.125 | 17.843 | 14.788 |
研究与开发 | 85.467 | 66.004 | 61.95 | 52.487 | 43.806 |
异常费用(收入) | 0 | 0 | 0 | 0 | |
营业收入 | -109.066 | -85.036 | -80.994 | -65.052 | -58.594 |
利息收入(费用),非经营净值 | 11.345 | 9.567 | 3.884 | 0.49 | 0.237 |
税前净收入 | -97.574 | -75.322 | -76.963 | -64.415 | -58.218 |
税后净收入 | -97.574 | -76.212 | -76.963 | -64.943 | -58.218 |
未计算非常项目前的净收益 | -97.574 | -76.212 | -76.963 | -64.943 | -58.218 |
净收入 | -97.574 | -76.212 | -76.963 | -64.943 | -58.218 |
普通股股东可获收益 (不含非经常性项目) | -97.574 | -76.212 | -76.963 | -64.943 | -58.218 |
普通股股东可获收益 (含非經常性項目) | -97.574 | -76.212 | -76.963 | -64.943 | -58.218 |
摊薄净收入 | -97.574 | -76.212 | -76.963 | -64.943 | -58.218 |
摊薄后加权平均股 | 34.8006 | 34.4367 | 32.3491 | 29.8963 | 29.806 |
扣除特别项目的每股摊薄盈利 | -2.8038 | -2.2131 | -2.37914 | -2.17227 | -1.95323 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -2.8038 | -2.2131 | -2.37914 | -2.17227 | -1.95323 |
其他,净值 | 0.147 | 0.147 | 0.147 | 0.147 | 0.139 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 1154.77 | 517.334 | 344.599 | 392.706 | 15.596 |
现金和短期投资 | 1124.04 | 493.991 | 322.33 | 389.397 | 13.887 |
现金等价物 | 248.329 | 206.953 | 53.048 | 208.929 | 8.904 |
短期投资 | 875.715 | 287.038 | 269.282 | 180.468 | 4.983 |
Prepaid Expenses | 27.757 | 20.43 | 20.776 | 2.824 | 1.686 |
Other Current Assets, Total | 2.911 | 1.163 | 1.493 | 0.485 | 0.023 |
Total Assets | 1163.33 | 527.671 | 347.625 | 393.024 | 15.857 |
Property/Plant/Equipment, Total - Net | 7.875 | 9.545 | 2.869 | 0.195 | 0.138 |
Property/Plant/Equipment, Total - Gross | 9.555 | 10.117 | 3.071 | 0.252 | 0.145 |
Accumulated Depreciation, Total | -1.68 | -0.572 | -0.202 | -0.057 | -0.007 |
Other Long Term Assets, Total | 0.69 | 0.792 | 0.157 | 0.123 | 0.123 |
Total Current Liabilities | 33.946 | 20.213 | 6.853 | 2.958 | 1.196 |
Accounts Payable | 2.379 | 1.939 | 0.865 | 0.547 | 0.269 |
Accrued Expenses | 31.567 | 18.274 | 5.988 | 2.411 | 0.538 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | ||||
Other Current Liabilities, Total | 0 | 0.389 | |||
Total Liabilities | 37.096 | 25.645 | 8.694 | 3.108 | 3.814 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 2.516 |
Long Term Debt | 0 | 2.516 | |||
Other Liabilities, Total | 3.15 | 5.432 | 1.841 | 0.15 | 0.102 |
Total Equity | 1126.24 | 502.026 | 338.931 | 389.916 | 12.043 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Preferred Stock - Non Redeemable, Net | 41.965 | ||||
Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0 |
Additional Paid-In Capital | 1693.73 | 790.391 | 482.955 | 465.42 | 1.633 |
Retained Earnings (Accumulated Deficit) | -564.207 | -287.871 | -144.066 | -75.512 | -31.555 |
Total Liabilities & Shareholders’ Equity | 1163.33 | 527.671 | 347.625 | 393.024 | 15.857 |
Total Common Shares Outstanding | 34.4739 | 29.7706 | 26.9885 | 26.0128 | 21.3729 |
Other Equity, Total | -3.29 | -0.497 | 0.039 | 0.005 | |
应收账款总额,净额 | 0.057 | 1.75 | |||
Accounts Receivable - Trade, Net | 0.057 | 1.75 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 1507.76 | 1154.77 | 1219.68 | 424.181 | 464.639 |
现金和短期投资 | 1474.45 | 1124.04 | 1192.03 | 407.414 | 443.187 |
现金等价物 | 562.66 | 248.329 | 628.317 | 136.096 | 176.203 |
短期投资 | 911.794 | 875.715 | 563.717 | 271.318 | 266.984 |
Prepaid Expenses | 25.487 | 27.757 | 24.353 | 10.193 | 19.026 |
Other Current Assets, Total | 7.818 | 2.911 | 3.21 | 1.824 | 2.426 |
Total Assets | 1516.17 | 1163.33 | 1228.41 | 433.556 | 474.474 |
Property/Plant/Equipment, Total - Net | 7.93 | 7.875 | 8.05 | 8.659 | 9.071 |
Other Long Term Assets, Total | 0.479 | 0.69 | 0.684 | 0.716 | 0.764 |
Total Current Liabilities | 25.237 | 33.946 | 40.745 | 23.868 | 15.923 |
Accounts Payable | 0.476 | 2.379 | 15.716 | 3.92 | 1.478 |
Accrued Expenses | 24.761 | 31.567 | 25.029 | 19.948 | 14.445 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | |||||
Total Liabilities | 28.033 | 37.096 | 44.457 | 28.147 | 20.786 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 2.796 | 3.15 | 3.712 | 4.279 | 4.863 |
Total Equity | 1488.14 | 1126.24 | 1183.95 | 405.409 | 453.688 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.004 | 0.003 | 0.003 | 0.003 | 0.003 |
Additional Paid-In Capital | 2151.53 | 1693.73 | 1675.65 | 819.433 | 802.309 |
Retained Earnings (Accumulated Deficit) | -661.781 | -564.207 | -487.995 | -411.032 | -346.089 |
Other Equity, Total | -1.615 | -3.29 | -3.698 | -2.995 | -2.535 |
Total Liabilities & Shareholders’ Equity | 1516.17 | 1163.33 | 1228.41 | 433.556 | 474.474 |
Total Common Shares Outstanding | 37.398 | 34.4739 | 34.346 | 29.9331 | 29.8313 |
应收账款总额,净额 | 0 | 0.057 | 0.081 | 4.75 | 0 |
Accounts Receivable - Trade, Net | 0 | 0.057 | 0.081 | 4.75 | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -276.336 | -143.805 | -68.554 | -43.957 | -17.512 |
经营活动产生的现金 | -228.006 | -100.878 | -69.856 | -30.923 | -15.377 |
经营活动产生的现金 | 1.112 | 0.506 | 0.145 | 0.058 | 0.006 |
非现金物品 | 42.444 | 31.576 | 14.133 | 12.377 | 3.985 |
营运资金的变化 | 4.774 | 10.845 | -15.58 | 0.599 | -1.856 |
投资活动产生的现金 | -586.395 | -22.688 | -89.65 | -174.335 | -5.115 |
资本支出 | -0.915 | -3.072 | -0.419 | -0.115 | -0.132 |
其他投资现金流量项目,总计 | -585.48 | -19.616 | -89.231 | -174.22 | -4.983 |
融资活动产生的现金 | 855.777 | 277.575 | 3.659 | 405.283 | 27.577 |
股票的发行(报废),净额 | 856.218 | 277.858 | 4.064 | 404.964 | 15.877 |
债务的发行(退还),净额 | 0 | 3.128 | 11.7 | ||
现金净变化 | 41.376 | 154.009 | -155.847 | 200.025 | 7.085 |
融资现金流项目 | -0.441 | -0.283 | -0.405 | -2.809 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -97.574 | -276.336 | -200.124 | -123.161 | -58.218 |
Cash From Operating Activities | -100.629 | -228.006 | -149.249 | -89.303 | -49.803 |
Cash From Operating Activities | 0.327 | 1.112 | 0.807 | 0.517 | 0.248 |
Non-Cash Items | 8.202 | 42.444 | 34.462 | 23.231 | 10.921 |
Changes in Working Capital | -11.584 | 4.774 | 15.606 | 10.11 | -2.754 |
Cash From Investing Activities | -27.491 | -586.395 | -279.779 | 12.241 | 17.796 |
Capital Expenditures | -0.714 | -0.915 | -0.625 | -0.451 | 0 |
Other Investing Cash Flow Items, Total | -26.777 | -585.48 | -279.154 | 12.692 | 17.796 |
Cash From Financing Activities | 442.451 | 855.777 | 850.392 | 6.205 | 1.257 |
Financing Cash Flow Items | -0.119 | -0.441 | -0.401 | -0.069 | -0.025 |
Issuance (Retirement) of Stock, Net | 442.57 | 856.218 | 850.793 | 6.274 | 1.282 |
Net Change in Cash | 314.331 | 41.376 | 421.364 | -70.857 | -30.75 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 14.7153 | 5510006 | 432391 | 2023-03-31 | LOW |
Capital International Investors | Investment Advisor | 9.0525 | 3389607 | 1694028 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.0495 | 3014042 | 266003 | 2023-03-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 6.6253 | 2480765 | 1278134 | 2023-03-31 | MED |
T. Rowe Price Associates, Inc. | Investment Advisor | 6.5406 | 2449052 | 117256 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5268 | 2069448 | 103020 | 2023-03-31 | LOW |
Sofinnova Investments, Inc | Venture Capital | 4.7354 | 1773124 | 0 | 2023-03-31 | MED |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 4.2914 | 1606854 | 551778 | 2023-03-31 | LOW |
PureTech Health, L.L.C. | Corporation | 4.0903 | 1531564 | -125000 | 2022-08-12 | LOW |
Viking Global Investors LP | Investment Advisor/Hedge Fund | 4.0089 | 1501074 | 317338 | 2023-03-31 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.6614 | 996535 | 20858 | 2023-03-31 | LOW |
Pivotal Bioventure Partners Investment Advisor LLC | Investment Advisor | 2.0885 | 782008 | 16113 | 2023-03-31 | LOW |
General Atlantic LLC | Private Equity | 1.9126 | 716158 | 0 | 2023-03-31 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 1.6723 | 626190 | 42808 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6089 | 602435 | 65948 | 2023-03-31 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 1.5049 | 563498 | 486506 | 2023-03-31 | HIGH |
Rock Springs Capital Management LP | Hedge Fund | 1.318 | 493527 | 79765 | 2023-03-31 | LOW |
Lord, Abbett & Co. LLC | Investment Advisor | 1.3117 | 491142 | -57179 | 2023-03-31 | MED |
Avidity Partners Management LP | Hedge Fund | 1.0784 | 403800 | 104800 | 2023-03-31 | LOW |
Eventide Asset Management, LLC | Investment Advisor | 0.9078 | 339898 | -179802 | 2023-03-31 | MED |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Karuna Therapeutics, Inc. Company profile
关于 Karuna Therapeutics Inc.
Karuna Therapeutics, Inc.是一家处于临床阶段的生物制药公司。 该公司专注于为精神病和神经病患者创造和提供变革性药物。 其主要候选产品KarXT是一种毒蕈碱受体的口服调节剂,该受体位于中枢神经系统(CNS)和各种外周组织。 该公司最初正在开发KarXT,用于治疗精神分裂症患者的急性精神病。 该公司用于治疗阿尔茨海默病(AD)的精神病,这是老年痴呆症相关精神病(DRP)的流行亚型。 KarXT是沙诺美林和特罗西泮的组合。 它正在推进一个治疗项目的管道,以解决与精神分裂症和老年痴呆症相关的阳性、阴性和认知症状(DRP)。 它的毒蕈碱受体具有多种生理作用,包括在认知、行为、感觉、运动和自主神经过程中。
Industry: | Bio Therapeutic Drugs |
99 High Street
26Th Floor
BOSTON
MASSACHUSETTS 02110
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。